Psyence Biomedical Ltd (PBM) Return on Assets ROA from the second quarter of 2025 to second quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Psyence Biomedical ltd   (NASDAQ: PBM)


Psyence Biomedical Ltd 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Psyence Biomedical Ltd 's ROA in the second quarter of 2025?
Psyence Biomedical Ltd recorded a cumulative net loss of $-52 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -930.22%.

However, within the Healthcare sector 56 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2024 from to 5263.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2025)
II. Quarter		 (Mar 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Total Assets Change 365.52 % 372.68 % -65.07 % -10.75 % 217.8 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -52 -51 -1 -1 -1
Return On Assets (TTM) -930.22 % -1672.23 % -34.2 % -53.82 % -52.47 %
PBM's Total Ranking # 5263 # # # #
Total Assets (TTM) in million 13 7 1 2 3
Seq. Total Assets Change 75.09 % 1253.36 % -66.1 % -42.05 % 77.78 %
Seq. Net Income Change - - - - -

PBM's 5 Years Annual ROA >> Back to PBM Management Effectiveness >> Compare PBM ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 24
Sector # 57
Overall # 391

Return On Assets Statistics
High Average Low
13.83 %
-1229.69 %
-4518.72 %
(Mar 31 2025)   (Mar 31 2024)



  News about Psyence Biomedical ltd Return on Assets ROA

Psyence Groups NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Psyence Biomedical Strengthens Its Scientific Advisory Board with Renowned Psychopharmacologist Dr. Dan J. Stein Amidst Ongoing ChallengesIn a strategic move aimed at enhancing its research capabilities, Psyence Group Inc. (Psyence Group) has announced a significant appointment to the Scientific Advisory Board of its NASDAQ-listed associate, Psyence Biomedical Ltd. (NASDAQ: PBM) (Psyence Biomed). The selection of Dr. Dan J. Stein, an esteemed figure in the realm of psychopharmacology, underscores the company’s commitment to advancing its drug development initiatives, particularly in the therapeutic applications of psychedelic medicine.Dr. Dan J. Stein, a recognized authority in psychopharmacology, brings with him a wealth of experience and a robust academic background. His expertise will undoubtedly bolster the ongoing scientific inquiries at Psyence Biomedical, particularly in optimizing their clinical trial designs and interpreting data. The addition of such a prominent figure to the Scientific Advisory Board has been hailed by company executives as an opportunity to harness innovative approaches in the evaluation of psychedelic compounds for therapeutic use.

Psyence Group's Associate Psyence Biomedical Expands Reach with Export of Psilocybin to Australia and Shares Updates on Phase IIb Trial.


Psyence Group s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 - Psyence Group Inc (Psyence Group) (CSE: PSYG), a life science biotechnology company specializing in the use of nature-derived psilocybin for mental health and wellbeing, is excited to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (PBM or Psyence Biomed), has recently exported nature-derived psilocybin to Australia and shared an update on their upcoming Phase IIb clinical trial.
Psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, has shown great potential in treating various mental health disorders. Psyence Group, in collaboration with its associate Psyence Biomed, has been at the forefront of exploring the therapeutic benefits of psilocybin.



Financial Statements
Psyence Biomedical Ltd 's Assets $ 13 million PBM's Balance sheet
Psyence Biomedical Ltd 's Income $ -1 million Quarterly PBM's Income Statement
PBM's Income by Division See PBM's Income by Division



Annual Return On Assets (Mar 31 2025)
FY 2025		 (Mar 31 2024)
FY 2024		 (Jan 31 2023)
FY 2023		 (Jan 31 2022)
FY 2022		 (Jan 31 2021)
FY 2021
Y / Y Total Assets Change 297.09 % -2.94 % -10.75 % -92.58 % -1.33 %
Total Assets in million 6 2 2 2 24
Y / Y Net Income Change - - - - -
Net Income in million 1 -51 -3 -26 0
Annual Return On Assets 16.46 % -3305.18 % -201.07 % -1474.94 % -2.05 %

PBM's 5 Years Annual ROA >> Back to PBM Management Effectiveness >> Compare PBM ROA to its Competitors



Comment on PBM's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 16.46 % compared to prior year, due to annual net income growth of % to $1.01 million, while value of Psyence Biomedical Ltd 's overall assets grew just by 297.09 % to $6.15 million, compared to $6.15 a year before.


More Return On Assets Ratios
PBM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PBM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PBM's Competitors
Subscribers only: Roa for Psyence Biomedical Ltd 's Suppliers
Subscribers only: Return On Assets for PBM's Customers

You may also want to know
PBM's Roi PBM's Inventory Turnover Ratio PBM's Growth Rates PBM's Dividend Comparisons
PBM's Profitability Ratios PBM's Asset Turnover Ratio PBM's Dividend Growth
PBM's Roe PBM's Valuation Ratios PBM's Financial Strength Ratios PBM's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector ROA

Date modified: 2026-07-07T12:30:57+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.